NCT05200000 is a Phase 1 clinical trial of SygeLIX-Coll-T in Keratitis, Ulcerative, sponsored by TBF Genie Tissulaire.

Who is sponsoring NCT05200000?

NCT05200000 is sponsored by TBF Genie Tissulaire.

What drugs are being tested in NCT05200000?

Interventions in NCT05200000: SygeLIX-Coll-T.

What condition does NCT05200000 study?

NCT05200000 studies Keratitis, Ulcerative, Corneal Ulcer.

Is NCT05200000 still recruiting?

NCT05200000 is currently completed. Last updated 20 February 2024.

Last reviewed 2024-02-20 · How we verify

NCT05200000

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Wharton's Jelly Eye Drops in the Treatment of Chronic Keratitis

Completed Phase 1 Last updated 20 February 2024

What this trial tests

Phase 1 trial testing SygeLIX-Coll-T in Keratitis, Ulcerative in 20 participants. Completed in 20 June 2023.

Timeline

8 January 2020

Primary endpoint
20 June 2023

20 June 2023

Quick facts

Lead sponsor	TBF Genie Tissulaire
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	8 January 2020
Primary completion	20 June 2023
Estimated completion	20 June 2023
Sites	6 locations across France

Drugs / interventions tested

SygeLIX-Coll-T — full drug profile →

Conditions studied

Keratitis, Ulcerative — all drugs for Keratitis, Ulcerative →
Corneal Ulcer — all drugs for Corneal Ulcer →

Sponsor

TBF Genie Tissulaire — full company profile →

Who can join

Adults 18 to 70, any sex, with Keratitis, Ulcerative or Corneal Ulcer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this open, non-comparative, multicenter trial is to assess the impact of eye drops made of Wharton's jelly extract in the treatment of chronic keratitis that failed available therapies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Biomedical Application of MSCs in Corneal Regeneration and Repair.
De Miguel MP, Cadenas-Martin M, Stokking M, Martin-Gonzalez AI. · · 2025 · cited 7× · PMID 39859409 · DOI 10.3390/ijms26020695

Verify or expand the search:

Other TBF Genie Tissulaire trials

Trials by the same sponsor.

NCT05638139 — Treatment of Ano-perineal Fistulas Resistant to Surgical Treatment with a Gel and Plug of Wharton's Jelly · Phase 1 · completed
NCT05302609 — Evaluation of SclerFIX Graft in Scleral Thinning After Exeresis of Tumors of the Ocular Surface · Phase 2 · terminated
NCT05247658 — Use of a Disk of Amniotic Membrane (Visio-AMTRIX) in Postoperative Care After PKR · Phase 3 · terminated
NCT05207189 — Biological Sling Allograft (UVT) for the Treatment of Urinary Incontinence in Women Presenting With Synthetic Sling Comp · Phase 2 · completed
NCT05250726 — Use of a Treated, Devitalized and Sterile Meniscus Segment (MENISC-T) in the Treatment of Scaphotrapeziotrapezoid Osteoa · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05200000 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by TBF Genie Tissulaire
Last refreshed: 20 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05200000.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing